drughunter.com
2 minute read
Jun. 2, 2018

A Trick to Fluorinate Grignards

drughunter.com
Drug Hunter Team
Loading...
Join Drug Hunter to access scientifically rich molecule case studies, patent highlights, and structure search to spark research ideas in minutes. Get in touch by filling out the form below and a Drug Team member will be in touch with you and your team shortly.
Loading...

twitterlinkedinemail

Other articles you may be interested in

Deucravacitinib: 2022 Small Molecule of the Year

We asked the global drug discovery community to nominate and vote on their favorite molecule from 2022, and the results are in. The 2022 winner, with the most overall votes across the ten finalist molecules , is BMS’ oral, deuterated allosteric TYK2 inhibitor, deucravacitinib, the first new treatment for plaque psoriasis in nearly a decade [...]

MK-0616: The 2023 Molecule of the Year

We asked the global drug discovery community to nominate and vote on their favorite molecule from 2023, and the results are in. The 2023 winner, with the most votes between ten molecules, is Merck’s oral macrocyclic peptide inhibitor of PCSK9, MK-0616, derived from mRNA display technology and shown to have clinical efficacy. Herein, we highlight what makes MK-0616 so impressive to the drug discovery community.

2023 Novel Small Molecule FDA Drug Approvals

The 34 small molecule drug approvals of 2023 are summarized in this poster and article with the structures, mechanisms of action, originators (& marketers), indications, and links to deep-dive reviews and more information about each drug.

2023 Molecules of the Year: Nominate!

The final set of Molecules of the Month for 2023 is out, and now it’s time to nominate your favorite molecules for 2023’s Molecules of the Year! Nominees should have either been first disclosed in 2023 or had a major new update in 2023 (e.g. clinical trial readout, publication, business transaction, approval). The molecule must have a [...]

From Lab to Leadership: Shaping the Next Generation of Drug Hunters

The impact of small and mid-sized biotech companies has become increasingly important. The shift from large pharma dominance to a biotech-driven era of drug discovery presents challenges to the traditional model of education for emerging medicinal chemists. Industry leader Dean Brown recently highlighted challenges for modern medicinal chemists starting in biotech who face fewer mentoring opportunities and are often propelled into leadership positions sooner than their counterparts in big pharma. Here we share how our team of former industry scientists at Drug Hunter can help.